Interpreting Therapeutic Effect in Multiple Sclerosis Via MRI Contrast Enhancing Lesions: Now You See Them, Now You Don't

Overview

Journal J Neurol

Specialty Neurology

Date 2014 Feb 27

PMID 24570281

Citations 4

Authors

Ilana R Leppert

S Narayanan

D Araujo

P S Giacomini

Y Lapierre

D L Arnold

G B Pike

Affiliations

Soon will be listed here.

Abstract

Gadolinium (Gd) enhancement of multiple sclerosis (MS) lesions on MRI scans is a commonly used outcome measure in therapeutic trials. However, enhancement depends on MRI acquisition parameters that might significantly alter detectability. We investigated how the difference in blood-brain barrier (BBB) permeability threshold between MRI protocols affects lesion detection and apparent enhancement time using dynamic-contrast-enhanced (DCE) MRI. We examined fourty-four relapsing-remitting MS patients with two MRI protocols: 'standard sensitivity' (SS) (1.5 T, single-dose Gd) and 'high sensitivity' (HS) (3 T, triple-dose Gd, delayed acquisition). Eleven patients had at least one enhancing lesion and completed the 1-month follow-up. We acquired DCE-MRI during the HS protocol and calculated BBB permeability. Sixty-five lesions were enhanced with the SS vs. 135 with the HS protocol. The detection threshold of the HS was significantly lower than that of the SS protocol (K trans = 2.64 vs. 4.00E-3 min(-1), p < 0.01). Most lesions (74 %) were in the recovery phase; none were in the onset phase and 26 % were at the peak of enhancement. The estimated duration of detectability with the HS protocol was significantly longer than for the SS protocol (6-12 weeks vs. 3 weeks). Our observations on the protocol-dependent threshold for detection and time-course help explain discrepancies in the observed effects of anti-inflammatory therapies on MS lesions.

Citing Articles

MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis.

Maranzano J, Rudko D, Nakamura K, Cook S, Cadavid D, Wolansky L Neurology. 2017; 89(7):714-721.

PMID: 28724581 PMC: 5562966. DOI: 10.1212/WNL.0000000000004227.

Evolving role of MRI in optimizing the treatment of multiple sclerosis: Canadian Consensus recommendations.

Arnold D, Li D, Hohol M, Chakraborty S, Chankowsky J, Alikhani K Mult Scler J Exp Transl Clin. 2017; 1:2055217315589775.

PMID: 28607695 PMC: 5433339. DOI: 10.1177/2055217315589775.

MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b.

Brown R, Narayanan S, Stikov N, Cook S, Cadavid D, Wolansky L Neurology. 2016; 87(9):905-11.

PMID: 27473139 PMC: 5035157. DOI: 10.1212/WNL.0000000000003043.

MRI in multiple sclerosis: an intra-individual, randomized and multicentric comparison of gadobutrol with gadoterate meglumine at 3 T.

Saake M, Langner S, Schwenke C, Weibart M, Jansen O, Hosten N Eur Radiol. 2015; 26(3):820-8.

PMID: 26123410 DOI: 10.1007/s00330-015-3889-7.

References

Yong V . Differential mechanisms of action of interferon-beta and glatiramer aetate in MS. Neurology. 2002; 59(6):802-8. DOI: 10.1212/wnl.59.6.802. View

Francis G . Importance of benefit-to-risk assessment for disease-modifying drugs used to treat MS. J Neurol. 2004; 251 Suppl 5:v42-v49. DOI: 10.1007/s00415-004-1507-8. View

Filippi M, Mastronardo G, Bastianello S, Rocca M, Rovaris M, Gasperini C . A longitudinal brain MRI study comparing the sensitivities of the conventional and a newer approach for detecting active lesions in multiple sclerosis. J Neurol Sci. 1998; 159(1):94-101. DOI: 10.1016/s0022-510x(98)00144-0. View

Lavini C, Verhoeff J . Reproducibility of the gadolinium concentration measurements and of the fitting parameters of the vascular input function in the superior sagittal sinus in a patient population. Magn Reson Imaging. 2010; 28(10):1420-30. DOI: 10.1016/j.mri.2010.06.017. View

Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann H . Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005; 40(11):715-24. DOI: 10.1097/01.rli.0000184756.66360.d3. View

Wattjes M, Lutterbey G, Harzheim M, Gieseke J, Traber F, Klotz L . Higher sensitivity in the detection of inflammatory brain lesions in patients with clinically isolated syndromes suggestive of multiple sclerosis using high field MRI: an intraindividual comparison of 1.5 T with 3.0 T. Eur Radiol. 2006; 16(9):2067-73. DOI: 10.1007/s00330-006-0195-4. View

Petkau J, Reingold S, Held U, Cutter G, Fleming T, Hughes M . Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses. Mult Scler. 2008; 14(6):770-8. PMC: 2692530. DOI: 10.1177/1352458507088104. View

Wolansky L, Bardini J, Cook S, ZIMMER A, Sheffet A, Lee H . Triple-dose versus single-dose gadoteridol in multiple sclerosis patients. J Neuroimaging. 1994; 4(3):141-5. DOI: 10.1111/jon199443141. View

Livshits I, Hussein S, Kennedy C, Weinstock-Guttman B, Hojnacki D, Zivadinov R . Comparison of a 1.5T standard vs. 3T optimized protocols in multiple sclerosis patients. Minerva Med. 2012; 103(2):97-102. View

10.

Barkhof F, Held U, Simon J, Daumer M, Fazekas F, Filippi M . Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials. Neurology. 2005; 65(9):1447-54. DOI: 10.1212/01.wnl.0000183149.87975.32. View

11.

Mikol D, Barkhof F, Chang P, Coyle P, Jeffery D, Schwid S . Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008; 7(10):903-14. DOI: 10.1016/S1474-4422(08)70200-X. View

12.

OConnor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D . 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009; 8(10):889-97. DOI: 10.1016/S1474-4422(09)70226-1. View

13.

Silver N, Good C, Barker G, MacManus D, Thompson A, Moseley I . Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain. 1997; 120 ( Pt 7):1149-61. DOI: 10.1093/brain/120.7.1149. View

14.

Erskine M, Cook L, Riddle K, Mitchell J, Karlik S . Resolution-dependent estimates of multiple sclerosis lesion loads. Can J Neurol Sci. 2005; 32(2):205-12. DOI: 10.1017/s031716710000398x. View

15.

Tofts P . Optimal detection of blood-brain barrier defects with Gd-DTPA MRI-the influences of delayed imaging and optimised repetition time. Magn Reson Imaging. 1996; 14(4):373-80. DOI: 10.1016/0730-725x(96)00023-9. View

16.

Durelli L, Clerico M . Comparison of immunomodulatory treatments for multiple sclerosis. Eur J Neurol. 2005; 12(11):915. DOI: 10.1111/j.1468-1331.2005.01372.x. View

17.

Dhib-Jalbut S . Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology. 2002; 58(8 Suppl 4):S3-9. DOI: 10.1212/wnl.58.8_suppl_4.s3. View

18.

Sormani M, Bonzano L, Roccatagliata L, Cutter G, Mancardi G, Bruzzi P . Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol. 2009; 65(3):268-75. DOI: 10.1002/ana.21606. View

19.

Sicotte N, Voskuhl R, Bouvier S, Klutch R, Cohen M, Mazziotta J . Comparison of multiple sclerosis lesions at 1.5 and 3.0 Tesla. Invest Radiol. 2003; 38(7):423-7. DOI: 10.1097/01.RLI.0000065426.07178.f1. View

20.

Gay D, Esiri M . Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytological study. Brain. 1991; 114 ( Pt 1B):557-72. DOI: 10.1093/brain/114.1.557. View